Vous êtes sur la page 1sur 6

Processed and formatted by SEC Watch - Visit SECWatch.

com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 19, 2009

MEDTOX SCIENTIFIC, INC.


(Exact n am e of re gistran t as spe cifie d in its ch arte r)

Delaware 1-11394 95-3863205


(State or oth e r jurisdiction (C om m ission File Nu m be r) (IRS Em ploye r
of in corporation ) Ide n tification No.)

402 West County Road D, St. Paul, Minnesota 55112


(Addre ss of prin cipal e xe cu tive office s) (Zip C ode )

Registrant’s telephone number, including area code: (651) 636-7466

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1
Processed and formatted by SEC Watch - Visit SECWatch.com
Item 8.01. Other Events

On February 19, 2009, MEDTOX Scientific, Inc. announced that it received 510(k) clearance from the U.S. Food and
Drug Administration (FDA) to market its PROFILE®-V MEDTOXScan® Drugs-of-Abuse Test System, as described
in the press release attached as Exhibit 99.1.

2
Processed and formatted by SEC Watch - Visit SECWatch.com
Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

The following exhibit is filed as part of this report:

Exhibit No. Description


99.1 MEDTOX Scientific, Inc. Press Release, dated February 19, 2009.

3
Processed and formatted by SEC Watch - Visit SECWatch.com
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.

MEDTOX Scientific, Inc.

Date: February 20, 2009 By: /s/ Richard J. Braun


Name: Richard J. Braun
Title: Chief Executive Officer

4
Processed and formatted by SEC Watch - Visit SECWatch.com
INDEX TO EXHIBITS

Exhibit No. Description


99.1 MEDTOX Scientific, Inc. Press Release, dated February 19, 2009.

Exhibit 99.1
MEDTOX Scientific, Inc.
402 West County Road D®
St. Paul, MN 55112
Contact: Paula Perry (877) 715-7236

FOR IMMEDIATE RELEASE

MEDTOX SCIENTIFIC RECEIVES FDA 510(K) CLEARANCE FOR


PROFILE(r)-V MEDTOXScan(r) DRUGS-OF-ABUSE TEST SYSTEM

ST. PAUL, February 19, 2009 – MEDTOX Scientific, Inc. (Nasdaq:MTOX), announced today that on February
13, 2009, it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its
PROFILE(r)-V MEDTOXScan(r) Drugs-of-Abuse Test System.

The PROFILE(r)-V MEDTOXScan(r) Drugs-of-Abuse Test System consists of the PROFILE®-V


MEDTOXScan® Test Devices and the MEDTOXScan® Reader. The Test Devices are one-step
immunochromatographic tests for the rapid qualitative detection of one or more of the following drug classes
and cutoff concentrations in human urine:

AMP Amphetamine 500 ng/mL


BAR Barbiturates 200 ng/mL
BZO Benzodiazepines 150 ng/mL
COC Cocaine 150 ng/mL
MAMP Methamphetamine 500 ng/mL
MTD Methadone 200 ng/mL
OPI Opiates 100 ng/mL
PCP Phencyclidine 25 ng/mL
THC Cannabinoids 50 ng/mL

The Reader provides accurate, easy-to-use and cost effective testing for drugs-of-abuse. Results are available in
10 minutes for improved turn around time. There is an optional attached bar-code scanner for accurate entry of
user ID, patient ID and lot number of the device. Test results will remain on the digital display until cleared by
the operator. A printer provides a paper copy of the results for a permanent record. The Reader also has network
integration capabilities, enhanced record storage of 1,000 results with improved record management.

The MEDTOXScan(r) Reader includes a Positive QC Test Device, a Negative QC Test Device and a Cleaning
Cassette. The Positive and Negative QC Test Devices are intended to detect potential errors associated with the
Reader such as a contaminated contact imaging sensor (CIS) and to verify the CIS cleaning procedure using the
approved Cleaning Cassette which effectively removed any contamination.
Processed and formatted by SEC Watch - Visit SECWatch.com
The Test System is intended for professional use in a hospital laboratory setting. Currently MEDTOX has
between 300 and 400 hospital clients utilizing MEDTOX’s PROFILE® visually read cassettes for drugs-of-abuse
detection. The new Test System will be marketed not only to those clients, but to the broader hospital market
which is estimated in excess of 2,500 hospitals.

See accompanying photo at http://www.globenewswire.com/newsroom/prs/?pkgid=5901

MEDTOX Scientific, Inc., headquartered in St. Paul, Minn., is a provider of high quality specialized laboratory
testing services and on-site/point-of-collection testing (POCT) devices. The company also supports customers
with complete logistics, data and program management services. MEDTOX is a leader in providing esoteric
laboratory testing services to hospitals and laboratories nationwide. This includes both central laboratory and
bio-analytical testing for pharmaceutical clinical trials. MEDTOX develops and manufactures diagnostic devices
for quick and economical on-site/point-of-collection analysis for drugs-of-abuse, therapeutic drugs and
biological and agricultural toxins and provides employment drug screening and occupational health testing. For
more information see www.medtox.com.